Free Trial
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free HTFL Stock Alerts

Heartflow (HTFL) Competitors

Heartflow logo
$28.80 -0.05 (-0.17%)
Closing price 06/4/2026 03:59 PM Eastern
Extended Trading
$28.87 +0.07 (+0.25%)
As of 05:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

HTFL vs. CELC, PACS, HIMS, CAI, and BLLN

Should you buy Heartflow stock or one of its competitors? MarketBeat compares Heartflow with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Heartflow include Celcuity (CELC), PACS Group (PACS), Hims & Hers Health (HIMS), Caris Life Sciences (CAI), and Billiontoone (BLLN). These companies are all part of the "healthcare" industry.

How does Heartflow compare to Celcuity?

Heartflow (NASDAQ:HTFL) and Celcuity (NASDAQ:CELC) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

Heartflow has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Heartflow, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Heartflow$176.03M14.11-$116.79M-$3.11N/A
CelcuityN/AN/A-$177.04M-$3.90N/A

Heartflow presently has a consensus target price of $37.00, indicating a potential upside of 28.46%. Celcuity has a consensus target price of $152.09, indicating a potential upside of 64.48%. Given Celcuity's stronger consensus rating and higher possible upside, analysts plainly believe Celcuity is more favorable than Heartflow.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Heartflow
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56
Celcuity
1 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.83

Celcuity has a net margin of 0.00% compared to Heartflow's net margin of -58.42%. Heartflow's return on equity of 0.00% beat Celcuity's return on equity.

Company Net Margins Return on Equity Return on Assets
Heartflow-58.42% N/A -20.02%
Celcuity N/A -244.61%-50.22%

63.3% of Celcuity shares are owned by institutional investors. 7.7% of Heartflow shares are owned by insiders. Comparatively, 13.3% of Celcuity shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Celcuity had 32 more articles in the media than Heartflow. MarketBeat recorded 34 mentions for Celcuity and 2 mentions for Heartflow. Heartflow's average media sentiment score of 0.61 beat Celcuity's score of 0.22 indicating that Heartflow is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Heartflow
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Celcuity
4 Very Positive mention(s)
4 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
6 Very Negative mention(s)
Neutral

Summary

Heartflow and Celcuity tied by winning 7 of the 14 factors compared between the two stocks.

How does Heartflow compare to PACS Group?

Heartflow (NASDAQ:HTFL) and PACS Group (NYSE:PACS) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

PACS Group has a net margin of 4.49% compared to Heartflow's net margin of -58.42%. PACS Group's return on equity of 26.47% beat Heartflow's return on equity.

Company Net Margins Return on Equity Return on Assets
Heartflow-58.42% N/A -20.02%
PACS Group 4.49%26.47%4.36%

In the previous week, Heartflow had 1 more articles in the media than PACS Group. MarketBeat recorded 2 mentions for Heartflow and 1 mentions for PACS Group. Heartflow's average media sentiment score of 0.61 beat PACS Group's score of 0.00 indicating that Heartflow is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Heartflow
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
PACS Group
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Heartflow presently has a consensus price target of $37.00, suggesting a potential upside of 28.46%. PACS Group has a consensus price target of $48.00, suggesting a potential upside of 28.05%. Given Heartflow's higher probable upside, research analysts plainly believe Heartflow is more favorable than PACS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Heartflow
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56
PACS Group
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.71

PACS Group has higher revenue and earnings than Heartflow. Heartflow is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Heartflow$176.03M14.11-$116.79M-$3.11N/A
PACS Group$5.43B1.09$191.54M$1.5624.03

Summary

PACS Group beats Heartflow on 8 of the 13 factors compared between the two stocks.

How does Heartflow compare to Hims & Hers Health?

Hims & Hers Health (NYSE:HIMS) and Heartflow (NASDAQ:HTFL) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

Hims & Hers Health has a net margin of -0.56% compared to Heartflow's net margin of -58.42%. Hims & Hers Health's return on equity of 6.10% beat Heartflow's return on equity.

Company Net Margins Return on Equity Return on Assets
Hims & Hers Health-0.56% 6.10% 1.52%
Heartflow -58.42%N/A -20.02%

63.5% of Hims & Hers Health shares are owned by institutional investors. 11.8% of Hims & Hers Health shares are owned by insiders. Comparatively, 7.7% of Heartflow shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Hims & Hers Health currently has a consensus target price of $28.70, indicating a potential upside of 2.21%. Heartflow has a consensus target price of $37.00, indicating a potential upside of 28.46%. Given Heartflow's stronger consensus rating and higher probable upside, analysts plainly believe Heartflow is more favorable than Hims & Hers Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hims & Hers Health
2 Sell rating(s)
11 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.12
Heartflow
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56

In the previous week, Hims & Hers Health had 17 more articles in the media than Heartflow. MarketBeat recorded 19 mentions for Hims & Hers Health and 2 mentions for Heartflow. Hims & Hers Health's average media sentiment score of 0.84 beat Heartflow's score of 0.61 indicating that Hims & Hers Health is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Hims & Hers Health
7 Very Positive mention(s)
6 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Heartflow
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Hims & Hers Health has higher revenue and earnings than Heartflow. Hims & Hers Health is trading at a lower price-to-earnings ratio than Heartflow, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hims & Hers Health$2.35B2.77$128.37M-$0.09N/A
Heartflow$176.03M14.11-$116.79M-$3.11N/A

Summary

Hims & Hers Health beats Heartflow on 10 of the 15 factors compared between the two stocks.

How does Heartflow compare to Caris Life Sciences?

Caris Life Sciences (NASDAQ:CAI) and Heartflow (NASDAQ:HTFL) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

In the previous week, Caris Life Sciences had 1 more articles in the media than Heartflow. MarketBeat recorded 3 mentions for Caris Life Sciences and 2 mentions for Heartflow. Heartflow's average media sentiment score of 0.61 beat Caris Life Sciences' score of 0.40 indicating that Heartflow is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Caris Life Sciences
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Heartflow
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Caris Life Sciences has higher revenue and earnings than Heartflow. Heartflow is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Caris Life Sciences$812.03M6.02-$68.09M-$7.61N/A
Heartflow$176.03M14.11-$116.79M-$3.11N/A

Caris Life Sciences currently has a consensus target price of $27.56, suggesting a potential upside of 59.47%. Heartflow has a consensus target price of $37.00, suggesting a potential upside of 28.46%. Given Caris Life Sciences' higher possible upside, analysts plainly believe Caris Life Sciences is more favorable than Heartflow.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Caris Life Sciences
1 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.45
Heartflow
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56

Caris Life Sciences has a net margin of 3.75% compared to Heartflow's net margin of -58.42%. Caris Life Sciences' return on equity of 98.28% beat Heartflow's return on equity.

Company Net Margins Return on Equity Return on Assets
Caris Life Sciences3.75% 98.28% 48.87%
Heartflow -58.42%N/A -20.02%

Summary

Caris Life Sciences beats Heartflow on 8 of the 12 factors compared between the two stocks.

How does Heartflow compare to Billiontoone?

Heartflow (NASDAQ:HTFL) and Billiontoone (NASDAQ:BLLN) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Billiontoone has a net margin of 0.00% compared to Heartflow's net margin of -58.42%.

Company Net Margins Return on Equity Return on Assets
Heartflow-58.42% N/A -20.02%
Billiontoone N/A N/A N/A

In the previous week, Heartflow and Heartflow both had 2 articles in the media. Billiontoone's average media sentiment score of 1.38 beat Heartflow's score of 0.61 indicating that Billiontoone is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Heartflow
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Billiontoone
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Billiontoone has higher revenue and earnings than Heartflow. Heartflow is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Heartflow$176.03M14.11-$116.79M-$3.11N/A
Billiontoone$354.54M13.57$7.45M$0.55190.16

Heartflow currently has a consensus target price of $37.00, indicating a potential upside of 28.46%. Billiontoone has a consensus target price of $125.29, indicating a potential upside of 19.79%. Given Heartflow's stronger consensus rating and higher possible upside, analysts clearly believe Heartflow is more favorable than Billiontoone.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Heartflow
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56
Billiontoone
1 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

Billiontoone beats Heartflow on 7 of the 10 factors compared between the two stocks.

Get Heartflow News Delivered to You Automatically

Sign up to receive the latest news and ratings for HTFL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HTFL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HTFL vs. The Competition

Export
MetricHeartflowHealth Information Services IndustryMedical SectorNASDAQ Exchange
Market Cap$2.49B$322.31M$6.30B$12.44B
Dividend YieldN/A5.59%2.69%5.32%
P/E Ratio-9.26230.8023.7424.34
Price / Sales14.11130.62498.0394.98
Price / CashN/A47.1441.3955.53
Price / Book8.165.5310.046.72
Net Income-$116.79M-$22.78M$3.56B$337.03M
7 Day Performance-7.03%0.23%-1.04%-0.16%
1 Month Performance-3.87%1.70%2.18%3.74%
1 Year PerformanceN/A-9.65%28.95%34.34%

Heartflow Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HTFL
Heartflow
3.8539 of 5 stars		$28.80
-0.2%		$37.00
+28.5%		N/A$2.49B$176.03MN/A699
CELC
Celcuity
3.2164 of 5 stars		$130.91
-2.3%		$150.27
+14.8%		+671.9%$6.38BN/AN/A40
PACS
PACS Group
3.7448 of 5 stars		$38.00
-3.1%		$48.00
+26.3%		+268.9%$6.01B$5.29B24.3647,455
HIMS
Hims & Hers Health
2.5938 of 5 stars		$25.40
+0.8%		$28.70
+13.0%		-47.8%$5.88B$2.35BN/A2,442
CAI
Caris Life Sciences
4.7895 of 5 stars		$16.67
+8.4%		$27.56
+65.3%		N/A$4.71B$812.03MN/A1,846

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:HTFL) was last updated on 6/5/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel